Haemophilia is a rare inherited blood disorder where the body cannot form blood clots properly, leading to prolonged bleeding episodes. While there is currently no cure, modern treatment approaches focus on preventing or controlling bleeding, protecting joints from damage, and helping patients live active, fulfilling lives.

Understanding Treatment Goals for Haemophilia

When someone receives a diagnosis of haemophilia, the journey toward managing this lifelong condition begins with understanding what treatment can and cannot do. The primary goal of haemophilia treatment is not to cure the disease, but rather to prevent bleeding episodes before they occur, stop bleeding when it happens, and minimize long-term complications such as joint damage and disability^[1]. Treatment decisions depend heavily on the severity of the condition—whether a person has mild, moderate, or severe haemophilia—and on individual patient characteristics including age, lifestyle, and overall health^[3].

Modern haemophilia care follows guidelines established by medical societies and is typically delivered through specialized comprehensive haemophilia treatment centers, which are facilities staffed by teams of specialists including hematologists, nurses, physical therapists, and social workers^[8]. These centers provide coordinated care that addresses not just the bleeding disorder itself, but also its impact on daily life, mental health, and long-term well-being. Standard treatments approved by regulatory agencies have been used for decades, but researchers continue to explore innovative therapies in clinical trials, offering hope for improved outcomes and potentially transformative approaches to managing this complex condition^[1].

Standard Treatment Approaches

The foundation of haemophilia treatment is replacement therapy, which involves infusing the missing clotting factor into the bloodstream so that blood can clot properly^[8]. For haemophilia A, the most common form of the disease, patients receive factor VIII (eight) concentrates. For haemophilia B, they receive factor IX (nine) concentrates. These clotting factor products come in two main varieties: plasma-derived concentrates made from donated human blood plasma, and recombinant concentrates produced through genetic engineering that do not contain any human blood components^[8].

Plasma-derived factor concentrates are created from donated blood plasma that undergoes extensive testing and processing to remove or inactivate any potential viruses. The plasma from many donors is pooled together, then separated into its component proteins, including the clotting factors. These are then freeze-dried and undergo additional viral inactivation treatments before being packaged for medical use^[8]. Recombinant factor concentrates, first approved in 1992, represent a major advancement in safety because they are manufactured using DNA technology in laboratory settings and contain no human plasma, eliminating the risk of transmitting blood-borne viruses^[8].

Treatment can be delivered in two main ways: on-demand (episodic) therapy or prophylactic (preventive) therapy^[8]. On-demand therapy means that clotting factor is given only when bleeding occurs, with the goal of stopping the episode as quickly as possible. This approach is sometimes used for people with mild haemophilia who bleed infrequently. Prophylactic therapy, in contrast, involves regular scheduled infusions of clotting factor—often two to three times per week—to maintain a baseline level of clotting factor in the blood and prevent bleeding episodes from occurring in the first place^[12].

Multiple studies and clinical guidelines now recommend prophylactic therapy as the preferred approach for people with severe haemophilia, particularly when started early in childhood. The International Society on Thrombosis and Haemostasis recommends that patients with severe and moderately severe haemophilia A without inhibitors receive prophylactic treatment rather than waiting to treat bleeding events^[12]. This preventive strategy has been shown to reduce the total number of bleeding episodes, protect joints from repeated damage, prevent or slow the progression of joint disease, and significantly improve quality of life^[12].

Many patients and families learn to perform factor infusions at home, which provides several important benefits. Home treatment allows bleeding episodes to be addressed more quickly, before they become severe, reducing pain and preventing complications^[8]. For those on prophylaxis, home infusion provides flexibility and allows normal participation in school, work, and social activities. Children and adolescents are often taught to self-infuse, fostering independence and empowering them to take control of their own health care^[16].

Additional Standard Medications

Beyond clotting factor replacement, several other medications play important roles in haemophilia management. Desmopressin (also called DDAVP) is a hormone-based medication that can stimulate the body to release more of its own clotting factor^[9]. It is administered either as a slow injection into a vein or as a nasal spray. Desmopressin is most effective in people with mild haemophilia A and is sometimes used before minor procedures or dental work to temporarily boost clotting ability^[9].

Tranexamic acid (brand names include Lysteda and Cyklokapron) and another similar medication called aminocaproic acid (Amicar) belong to a class of drugs known as antifibrinolytics^[9]. These medicines help preserve blood clots after they form by preventing the body from breaking them down too quickly. They are particularly useful for bleeding in the mouth, nose, or other mucous membranes, and can be given as pills, liquid, or injection^[14].

For women and girls with haemophilia or who are carriers of the haemophilia gene, hormone therapy may be recommended to manage heavy menstrual bleeding^[13]. Birth control pills or hormonal intrauterine devices can help regulate and reduce menstrual flow, preventing the excessive blood loss that can occur during periods.

Treatment Duration and Management

Haemophilia treatment is lifelong. For those on prophylactic therapy, regular infusions typically begin in early childhood, often around age one or two, and continue into adolescence and adulthood^[12]. The frequency and dose of treatment are individualized based on bleeding patterns, activity level, and how quickly the body clears the clotting factor. Some patients require infusions three times weekly, while others may need them more or less frequently.

The dose of clotting factor is calculated to achieve specific target levels in the blood, which vary depending on the clinical situation^[12]. For mild bleeding episodes such as minor joint bleeds or superficial bruises, healthcare providers aim for clotting factor levels of 30 to 40 percent of normal. For severe bleeding, such as that following significant trauma, or for coverage before major surgery, target levels are at least 50 percent and sometimes as high as 80 to 100 percent of normal^[12].

Potential Side Effects and Complications

While modern clotting factor products are very safe, with extensive viral inactivation or no human blood components, some patients may develop complications. The most serious is the development of inhibitors—antibodies that the immune system produces against the infused clotting factor^[8]. These antibodies can neutralize the clotting factor, making treatment less effective or completely ineffective. Inhibitors develop in approximately 20 to 30 percent of people with severe haemophilia A and less frequently in haemophilia B. When inhibitors appear, treatment becomes more complex and may require specialized bypassing agents or immune tolerance therapy to eliminate the antibodies^[12].

Other potential side effects of treatment include allergic reactions to the infused product, though these are uncommon. Some patients experience pain, swelling, or irritation at the infusion site. With long-term repeated infusions, venous access can become difficult, sometimes necessitating placement of a central venous catheter or port, which itself carries risks of infection or blood clots.

Innovative Treatments in Clinical Trials

The landscape of haemophilia treatment has evolved dramatically in recent years, with several groundbreaking therapies now being tested in clinical trials or recently approved based on trial results. These innovations offer new hope, particularly for patients who have developed inhibitors or who find traditional factor replacement burdensome.

Non-Factor Replacement Therapies

One of the most significant recent advances is emicizumab (brand name Hemlibra), a medication that works differently from traditional clotting factor replacement^[9]. Emicizumab is a laboratory-made antibody that bridges two clotting proteins (factors IXa and X), mimicking the function of factor VIII without actually being factor VIII. This innovative approach offers several advantages: it can be given as a subcutaneous injection under the skin rather than intravenously, it has a longer duration of action allowing for weekly or even less frequent dosing, and it works in patients who have developed inhibitors against factor VIII^[8].

Clinical trials of emicizumab have demonstrated impressive results in preventing bleeding episodes. In Phase III studies comparing emicizumab prophylaxis to either no prophylaxis or to previous factor VIII prophylaxis in adults and adolescents with haemophilia A, participants receiving emicizumab experienced significantly fewer bleeding episodes^[9]. The medication has been studied in people both with and without inhibitors, and has shown efficacy in both populations. The convenience of subcutaneous administration and less frequent dosing has potential to significantly improve quality of life and treatment adherence.

Extended Half-Life Factor Concentrates

Researchers have developed modified versions of clotting factors that remain active in the bloodstream for longer periods than traditional products. These extended half-life factors are created by attaching molecules like polyethylene glycol (PEG) or fragments of antibodies (Fc fusion) to the clotting factor, which slows down how quickly the body breaks them down and clears them^[13].

Clinical trials have shown that extended half-life products allow for less frequent dosing—sometimes only once or twice weekly instead of three times weekly—while maintaining similar or better protection against bleeding compared to standard products. Phase III trials have evaluated these products in both previously treated and previously untreated patients with haemophilia A and B, with results showing good safety profiles and sustained efficacy over extended periods. The reduced treatment burden may particularly benefit patients who struggle with frequent infusions.

Gene Therapy: A Potentially Transformative Approach

Gene therapy represents perhaps the most revolutionary approach under investigation for haemophilia. The concept is elegantly simple yet scientifically complex: deliver a working copy of the gene for factor VIII or factor IX into a patient’s cells, allowing their body to produce the missing clotting factor on its own^[1]. If successful, this could transform haemophilia from a chronic condition requiring lifelong regular treatment into one requiring only a single intervention.

Gene therapy trials use modified viruses, most commonly adeno-associated viruses (AAV), as vehicles to carry the functional gene into the patient’s liver cells^[13]. The liver is targeted because it is the natural site of clotting factor production in the body. The modified virus infects liver cells and inserts the working gene into their genetic material, enabling them to produce clotting factor. Because the genetic modification occurs in long-lived liver cells, the effect can potentially last for many years or even a lifetime.

Several gene therapy products are currently in Phase III clinical trials for both haemophilia A and haemophilia B. Early and mid-phase trial results have been promising, with many participants showing sustained increases in their clotting factor levels—in some cases reaching levels that move them from severe to mild haemophilia or even into the normal range. Many trial participants have been able to discontinue or dramatically reduce their factor replacement therapy. Some have remained off regular prophylaxis for several years following a single gene therapy infusion.

However, gene therapy is not without challenges and uncertainties. Some patients experience immune responses to the viral vector or the newly produced clotting factor, which can reduce effectiveness or cause side effects. Temporary liver inflammation sometimes occurs, typically managed with immunosuppressive medications. The durability of the effect remains under investigation—while many patients maintain elevated factor levels for years, some experience a gradual decline over time. Long-term safety data, including any potential risk of cancer from genetic modification, are still being collected as trial participants are followed for many years^[1].

Gene therapy trials have primarily enrolled adults with severe haemophilia who have been on factor replacement therapy for many years. Participants must meet strict eligibility criteria, including having no pre-existing immunity to the viral vector used. Trials are being conducted at specialized medical centers in the United States, Europe, Australia, and other regions around the world.

RNA Interference Therapies

Another innovative approach involves using RNA interference to reduce the activity of natural anticoagulant proteins in the blood. One such therapy, fitusiran, works by silencing the gene for antithrombin, a protein that normally inhibits clot formation^[12]. By reducing antithrombin levels, fitusiran tips the balance toward more clotting, compensating for the lack of clotting factor in people with haemophilia.

Fitusiran is administered as a subcutaneous injection, typically once monthly. Phase I and II clinical trials demonstrated that it could reduce bleeding rates in people with haemophilia A or B, both with and without inhibitors. Phase III trials are currently evaluating its safety and efficacy compared to standard treatments and other newer therapies. One concern with this approach is the potential for excessive clotting, so careful monitoring and adherence to dosing protocols are essential.

Tissue Factor Pathway Inhibitor Antibodies

Researchers are also exploring therapies that block natural braking mechanisms in the clotting cascade. Tissue factor pathway inhibitor (TFPI) is a protein that normally puts limits on clot formation. By blocking TFPI with specially designed antibodies, the clotting process can proceed more efficiently even in the absence of normal amounts of factor VIII or IX^[12].

Several anti-TFPI antibodies are in various phases of clinical development. These molecules, with code names like concizumab and marstacimab, are being tested in Phase II and Phase III trials. Like some other newer therapies, they offer the potential advantage of subcutaneous administration and less frequent dosing compared to traditional factor replacement. Early trial results have shown reductions in bleeding rates, though research continues to fully establish their safety and optimal use.

Understanding Clinical Trial Phases

It’s important to understand what different clinical trial phases mean. Phase I trials are the earliest human studies, typically involving small numbers of participants, and focus primarily on safety—determining what doses can be given safely and what side effects occur^[12]. Phase II trials include more participants and begin to evaluate whether the treatment actually works—does it reduce bleeding, increase factor levels, or achieve other desired effects? These trials also continue to monitor safety. Phase III trials are large studies, often involving hundreds of participants at multiple sites, that compare the new treatment directly to existing standard treatments or placebo to definitively prove efficacy and further characterize safety. Only after successful Phase III trials can a treatment be submitted to regulatory agencies for approval.

Even after approval, Phase IV studies continue to monitor long-term safety and effectiveness in larger, more diverse populations and in real-world clinical practice. For haemophilia, Phase IV research is particularly important for monitoring the durability of newer treatments and detecting any rare adverse effects that might not appear until many people have been treated for extended periods.

Most Common Treatment Methods

• Clotting Factor Replacement Therapy
  • Plasma-derived factor concentrates made from pooled donated human blood plasma that undergoes extensive viral inactivation processing^[8]
  • Recombinant factor concentrates produced through genetic engineering without human blood components, first approved in 1992^[8]
  • Extended half-life factor products modified to remain active longer in the bloodstream, allowing less frequent dosing^[13]
  • Factor VIII infusions for haemophilia A and factor IX infusions for haemophilia B^[8]
  • On-demand (episodic) therapy given only when bleeding occurs to stop active episodes^[8]
  • Prophylactic (preventive) therapy with regular scheduled infusions two to three times weekly to prevent bleeding before it starts^[12]
• Non-Factor Therapies
  • Emicizumab (Hemlibra), a laboratory-made antibody that mimics factor VIII function, given as subcutaneous injection weekly or less frequently^[9]
  • Effective in patients with or without inhibitors to factor VIII^[8]
• Additional Medications
  • Desmopressin (DDAVP), a hormone that stimulates the body to release its own clotting factor, used primarily for mild haemophilia A^[9]
  • Antifibrinolytic medicines (tranexamic acid, aminocaproic acid) that prevent clot breakdown, particularly useful for mucosal bleeding in the mouth or nose^[14]
  • Hormone therapy for women and girls to manage heavy menstrual bleeding^[13]
• Gene Therapy
  • Investigational approach using modified viruses to deliver a working gene for factor VIII or IX into liver cells^[1]
  • Currently in Phase III clinical trials with promising results showing sustained factor level increases in many participants^[13]
  • Potential for long-lasting or permanent effect from single treatment, though long-term durability still being studied^[1]
• Investigational RNA and Antibody Therapies
  • RNA interference therapies like fitusiran that reduce natural anticoagulant proteins, administered monthly by subcutaneous injection^[12]
  • Tissue factor pathway inhibitor (TFPI) blocking antibodies that allow clotting to proceed more efficiently^[12]
  • Currently in Phase II and Phase III clinical trials^[12]
• Comprehensive Care Approaches
  • Multidisciplinary care teams at specialized hemophilia treatment centers including hematologists, nurses, physical therapists, and social workers^[8]
  • Home infusion programs where patients learn to self-administer treatment^[8]
  • Physical therapy to strengthen muscles, maintain joint flexibility, and manage complications of joint bleeding^[15]
  • Pain management strategies for acute bleeding episodes and chronic joint disease^[12]